Altimmune, Inc. (NASDAQ:ALT) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 86.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 34,436 shares of the company’s stock after selling 220,135 shares during the quarter. SG Americas Securities LLC’s holdings in Altimmune were worth $211,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank acquired a new position in Altimmune during the first quarter worth $1,079,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Altimmune during the first quarter worth $271,000. Sei Investments Co. acquired a new position in Altimmune during the first quarter worth $479,000. Commonwealth Equity Services LLC boosted its stake in Altimmune by 31.5% during the first quarter. Commonwealth Equity Services LLC now owns 79,945 shares of the company’s stock worth $814,000 after buying an additional 19,172 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Down 1.4 %

ALT stock opened at $6.80 on Wednesday. The company has a market capitalization of $482.13 million, a PE ratio of -4.28 and a beta of 0.08. Altimmune, Inc. has a 12-month low of $2.09 and a 12-month high of $14.84. The business’s fifty day moving average price is $6.74 and its 200 day moving average price is $6.93.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. During the same quarter in the previous year, the company earned ($0.32) EPS. Research analysts predict that Altimmune, Inc. will post -0.54 EPS for the current fiscal year.

Insider Activity at Altimmune

In related news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the sale, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Evercore ISI raised Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. Finally, B. Riley reaffirmed a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.80.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.